Novartis gained Swiss regulatory clearance for Coartem Baby, the first malaria treatment formulated specifically for newborns and young infants. The new dosing addresses an unmet need for safe, effective therapy in this vulnerable population. Novartis plans to supply the medicine largely on a not-for-profit basis in targeted regions, expanding access for early childhood malaria treatment.